Filamin A and parafibromin expression in parathyroid carcinoma

in European Journal of Endocrinology
View More View Less
  • 1 Endocrinology, Abdominal Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • | 2 Department of Pathology and Huslab, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • | 3 Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
  • | 4 Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Correspondence should be addressed to J Arola Email Johanna.T.Arola@Helsinki.Fi
Restricted access

Objective

Parathyroid carcinoma (PC), atypical parathyroid tumours (APT) and parathyroid adenoma (PA), all present with hypercalcemia. Diminished calcium-sensing receptor (CaSR) expression is reported in PC but is rare in benign tumours. Filamin A (FLNA) binds to the CaSR and activates the mitogen-activated protein kinase (MAPK) signalling pathway. FLNA is related to tumour aggressiveness in several cancers, but its role in parathyroid neoplasia is unknown.

Design

We examined FLNA, CaSR and parafibromin expression in PCs (n = 32), APTs (n = 44) and PAs (n = 77) and investigated their potential as diagnostic and/or prognostic markers.

Methods

Tissue microarray slides were immunohistochemically stained with antibodies for FLNA, CaSR and parafibromin. Staining results were correlated with detailed clinical data.

Results

All tumours stained positively for CaSR, with two tumours (one PC and one APT) showing diminished expression. Carcinomas were characterized by increased cytoplasmic FLNA expression compared to APTs and PAs (P  = 0.004). FLNA expression was not correlated with Ki-67 proliferation index or loss of parafibromin expression. Cytoplasmic FLNA expression was also associated with higher serum calcium, PTH concentrations and male sex (P  = 0.014, P  = 0.017 and P  = 0.049 respectively). Using a combined marker score, we found that parathyroid tumours with low FLNA expression and positive parafibromin staining were extremely likely to be benign (P  < 0.001).

Conclusion

Cytoplasmic and membranous FLNA expression is increased in parathyroid carcinomas compared to benign tumours. A combined FLNA and parafibromin expression score shows potential as a prognostic predictor of indolent behaviour in parathyroid neoplasms.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 543 543 447
Full Text Views 27 27 25
PDF Downloads 43 43 39
  • 1

    Duan K, Mete Ö. Parathyroid carcinoma: diagnosis and clinical implications. Turk Patoloji Dergisi 2015 31 (Supplement 1) 8097. (https://doi.org/10.5146/tjpath.2015.01316)

    • Search Google Scholar
    • Export Citation
  • 2

    Cetani F, Pardi E, Marcocci C. Parathyroid carcinoma. Frontiers of Hormone Research 2019 51 6376. (https://doi.org/10.1159/000491039)

  • 3

    Quinn CE, Healy J, Lebastchi AH, Brown TC, Stein JE, Prasad ML, Callender GG, Carling T, Udelsman R. Modern experience with aggressive parathyroid tumors in a high-volume new England referral center. Journal of the American College of Surgeons 2015 220 10541062. (https://doi.org/10.1016/j.jamcollsurg.2014.10.007)

    • Search Google Scholar
    • Export Citation
  • 4

    Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. Journal of Endocrinological Investigation 2016 39 595606. (https://doi.org/10.1007/s40618-016-0447-3)

    • Search Google Scholar
    • Export Citation
  • 5

    Juhlin CC, Erickson LA. Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice. Endocrine Pathology 2021 32 1734. (https://doi.org/10.1007/s12022-020-09656-9)

    • Search Google Scholar
    • Export Citation
  • 6

    Cetani F, Marcocci C, Torregrossa L, Pardi E. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocrine-Related Cancer 2019 26 R441R464. (https://doi.org/10.1530/ERC-19-0135)

    • Search Google Scholar
    • Export Citation
  • 7

    Ryhänen EM, Leijon H, Metso S, Eloranta E, Korsoff P, Ahtiainen P, Kekäläinen P, Tamminen M, Ristamäki R & Knutar O et al.A nationwide study on parathyroid carcinoma. Acta Oncologica 2012 56 11321144. (https://doi.org/10.1080/0284186X.2017.1306103)

    • Search Google Scholar
    • Export Citation
  • 8

    Witteveen JE, Hamdy NAT, Dekkers OM, Kievit J, van Wezel T, Teh BT, Romijn JA, Morreau H. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Modern Pathology 2011 24 688697. (https://doi.org/10.1038/modpathol.2010.236)

    • Search Google Scholar
    • Export Citation
  • 9

    Juhlin CC, Nilsson IL, Lagerstedt-Robinson K, Stenman A, Bränström R, Tham E, Höög A. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center. Modern Pathology 2019 32 10821094. (https://doi.org/10.1038/s41379-019-0252-6)

    • Search Google Scholar
    • Export Citation
  • 10

    Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 2009 115 334344. (https://doi.org/10.1002/cncr.24037)

    • Search Google Scholar
    • Export Citation
  • 11

    Iihara M, Okamoto T, Suzuki R, Kawamata A, Nishikawa T, Kobayashi M, Obara T. Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis. Surgery 2007 142 93694 3; discussion 943.e1. (https://doi.org/10.1016/j.surg.2007.09.014)

    • Search Google Scholar
    • Export Citation
  • 12

    Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, Robinson BG, Teh BT, Gimm O, Marsh DJ. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2009 94 434441. (https://doi.org/10.1210/jc.2008-1740)

    • Search Google Scholar
    • Export Citation
  • 13

    Silva-Figueroa AM, Bassett R, Christakis I, Moreno P, Clarke CN, Busaidy NL, Grubbs EG, Lee JE, Perrier ND, Williams MD. Using a novel diagnostic nomogram to differentiate malignant from benign parathyroid neoplasms. Endocrine Pathology 2019 30 285296. (https://doi.org/10.1007/s12022-019-09592-3)

    • Search Google Scholar
    • Export Citation
  • 14

    Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. Journal of Clinical Endocrinology and Metabolism 1996 81 17361739. (https://doi.org/10.1210/jcem.81.5.8626826)

    • Search Google Scholar
    • Export Citation
  • 15

    Chung DC Cyclin D1 in human neuroendocrine tumorigenesis. Annals of the New York Academy of Sciences 2004 1014 209217. (https://doi.org/10.1196/annals.1294.022)

    • Search Google Scholar
    • Export Citation
  • 16

    Brewer K, Costa-Guda J, Arnold A. Molecular genetic insights into sporadic primary hyperparathyroidism. Endocrine-Related Cancer 2019 26 R53R72. (https://doi.org/10.1530/ERC-18-0304)

    • Search Google Scholar
    • Export Citation
  • 17

    Farnebo F, Auer G, Farnebo LO, Teh BT, Twigg S, Aspenblad U, Thompson NW, Grimelius L, Larsson C, Sandelin K. Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World Journal of Surgery 1999 23 6874. (https://doi.org/10.1007/s002689900567)

    • Search Google Scholar
    • Export Citation
  • 18

    Pandya C, Uzilov AV, Bellizzi J, Lau CY, Moe AS, Strahl M, Hamou W, Newman LC, Fink MY & Antipin Y et al.Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight 2017 2 e92061. (https://doi.org/10.1172/jci.insight.92061)

    • Search Google Scholar
    • Export Citation
  • 19

    Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocrine Pathology 2010 21 166177. (https://doi.org/10.1007/s12022-010-9121-z)

    • Search Google Scholar
    • Export Citation
  • 20

    Bergero N, de Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Human Pathology 2005 36 908914. (https://doi.org/10.1016/j.humpath.2005.06.020)

    • Search Google Scholar
    • Export Citation
  • 21

    Kumari N, Chaudhary N, Pradhan R, Agarwal A, Krishnani N. Role of histological criteria and immunohistochemical markers in predicting risk of malignancy in parathyroid neoplasms. Endocrine Pathology 2016 27 8796. (https://doi.org/10.1007/s12022-016-9426-7)

    • Search Google Scholar
    • Export Citation
  • 22

    Tennakoon S, Aggarwal A, Kállay E. The calcium-sensing receptor and the hallmarks of cancer. Biochimica et Biophysica Acta 2016 1863 13981407. (https://doi.org/10.1016/j.bbamcr.2015.11.017)

    • Search Google Scholar
    • Export Citation
  • 23

    Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosomes Iq and IIq in parathyroid carcinoma. Journal of Pathology 2004 202 8694. (https://doi.org/10.1002/path.1489)

    • Search Google Scholar
    • Export Citation
  • 24

    Brennan SC, Thiem U, Roth S, Aggarwal A, Fetahu ISh, Tennakoon S, Gomes AR, Brandi ML, Bruggeman F & Mentaverri R et al.Calcium sensing receptor signalling in physiology and cancer. Biochimica et Biophysica Acta 2013 1833 17321744. (https://doi.org/10.1016/j.bbamcr.2012.12.011)

    • Search Google Scholar
    • Export Citation
  • 25

    Sungu N, Dogan HT, Kiliçarslan A, Kiliç M, Polat S, Tokaç M, Akbaba S, Parlak Ö, Balci S & Ögüt B et al.Role of calcium-sensing receptor, galectin-3, cyclin D1, and Ki-67 immunohistochemistry to favor in the diagnosis of parathyroid carcinoma. Indian Journal of Pathology and Microbiology 2018 61 2226. (https://doi.org/10.4103/IJPM.IJPM_85_17)

    • Search Google Scholar
    • Export Citation
  • 26

    Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M, Shapiro SS. Filamins as integrators of cell mechanigs and signalling. Nature Reviews: Molecular Cell Biology 2001 2 138145. (https://doi.org/10.1038/35052082)

    • Search Google Scholar
    • Export Citation
  • 27

    Hjälm G, MacLeod RJ, Kifor O, Chattopadhyay N, Brown EM. Filamin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase. Journal of Biological Chemistry 2001 276 3488034887. (https://doi.org/10.1074/jbc.M100784200)

    • Search Google Scholar
    • Export Citation
  • 28

    Awata H, Huang C, Handlogten ME, Miller RT. Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein. Journal of Biological Chemistry 2001 276 3487134879. (https://doi.org/10.1074/jbc.M100775200)

    • Search Google Scholar
    • Export Citation
  • 29

    Savoy RM, Ghosh PM. The dual role of filamin A in cancer: can’t live with (too much of) it, can’t live without it. Endocrine-Related Cancer 2013 20 R341R356. (https://doi.org/10.1530/ERC-13-0364)

    • Search Google Scholar
    • Export Citation
  • 30

    Baldassarre M, Razinia Z, Burande CF, Lamsoul I, Lutz PG, Calderwood DA. Filamins regulate cell spreading and initiation of cell migration. PLoS ONE 2009 4 e7830. (https://doi.org/10.1371/journal.pone.0007830)

    • Search Google Scholar
    • Export Citation
  • 31

    Zhong Z, Yeow WS, Zou C, Wassell R, Wang C, Pestell RG, Quong JN, Quong AA. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Research 2010 70 21052114. (https://doi.org/10.1158/0008-5472.CAN-08-1108)

    • Search Google Scholar
    • Export Citation
  • 32

    Vitali E, Boemi I, Rosso L, Cambiaghi V, Novellis P, Mantovani G, Spada A, Alloisio M, Veronesi G & Ferrero S et al.FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression. Oncotarget 2017 8 7733077340. (https://doi.org/10.18632/oncotarget.20473)

    • Search Google Scholar
    • Export Citation
  • 33

    Jiang X, Yue J, Lu H, Campbell N, Yang Q, Lan S, Haffty BG, Yuan C, Shen Z. Inhibition of filamin-A reduces cancer metastatic potential. International Journal of Biological Sciences 2013 9 6777. (https://doi.org/10.7150/ijbs.5577)

    • Search Google Scholar
    • Export Citation
  • 34

    Mingione A, Verdelli C, Ferrero S, Vaira V, Guarnieri V, Scillitani A, Vicentini L, Balza G, Beretta E & Terranegra A et al.Filamin A is reduced and contributes to the CASR sensitivity in human parathyroid tumors. Journal of Molecular Endocrinology 2017 58 91103. (https://doi.org/10.1530/JME-16-0184)

    • Search Google Scholar
    • Export Citation
  • 35

    Guo Y, Li M, Bai G, Li X, Sun Z, Yang J, Wang L, Sun J. Filamin a inhibits tumor progression through regulating BRCA1 expression in human breast cancer. Oncology Letters 2018 16 62616266. (https://doi.org/10.3892/ol.2018.9473)

    • Search Google Scholar
    • Export Citation
  • 36

    Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, Silva D, Ogino LL, Ventura N & Sánchez-Sánchez R et al.Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. Scientific Reports 2019 9 1122. (https://doi.org/10.1038/s41598-018-37692-3)

    • Search Google Scholar
    • Export Citation
  • 37

    Kim HK, Oh YL, Kim SH, Lee DY, Kang HC, Lee JI, Jang HW, Hur KY, Kim JH & Min YK et al.Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma FROM parathyroid adenoma. Head and Neck 2012 34 201206. (https://doi.org/10.1002/hed.21716)

    • Search Google Scholar
    • Export Citation
  • 38

    Nakamura F, Stossel TP, Hartwig JH. The filamins: organizers of cell structure and function. Cell Adhesion and Migration 2011 5 160169. (https://doi.org/10.4161/cam.5.2.14401)

    • Search Google Scholar
    • Export Citation
  • 39

    Zhang M, Breitwieser GE. High affinity interaction with filamin A protects against calcium-sensing receptor degradation. Journal of Biological Chemistry 2005 280 1114011146. (https://doi.org/10.1074/jbc.M412242200)

    • Search Google Scholar
    • Export Citation
  • 40

    Farnebo F, Enberg U, Grimelius L, Bäckdahl M, Schalling M, Larsson C, Farnebo LO. Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1997 82 34813486. (https://doi.org/10.1210/jcem.82.10.4300)

    • Search Google Scholar
    • Export Citation
  • 41

    Sulaiman L, Juhlin CC, Nilsson IL, Fotouhi O, Larsson C, Hashemi J. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism. Epigenetics 2013 8 646655. (https://doi.org/10.4161/epi.24823)

    • Search Google Scholar
    • Export Citation
  • 42

    Varshney S, Bhadada SK, Sachdeva N, Arya AK, Saikia UN, Behera A, Rao SD. Methylation status of the CpG islands in vitamin D and calcium-sensing receptor gene promoters does not explain the reduced gene expressions in parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 2013 98 E1631E1635. (https://doi.org/10.1210/jc.2013-1699)

    • Search Google Scholar
    • Export Citation
  • 43

    Singh P, Bhadada SK, Dahiya D, Arya AK, Saikia UN, Sachdeva N, Kaur J, Brandi ML, Rao SD. Reduced calcium sensing receptor (CaSR) expression is epigenetically deregulated in parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 2020 105 30153024. (https://doi.org/10.1210/clinem/dgaa419)

    • Search Google Scholar
    • Export Citation
  • 44

    Griffiths GS, Grundi M, Allen III JS, Matter ML. R-Ras interacts with filamin A to maintain endothelial barrier function. Journal of Cellular Physiology 2011 226 22872296. (https://doi.org/10.1002/jcp.22565)

    • Search Google Scholar
    • Export Citation
  • 45

    Yue J, Huhn S, Shen Z. Complex roles of filamin-A mediated cytoskeleton network in cancer progression. Cell and Bioscience 2013 3 7. (https://doi.org/10.1186/2045-3701-3-7)

    • Search Google Scholar
    • Export Citation
  • 46

    Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P & Miccoli P et al.Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? European Journal of Endocrinology 2007 156 547554. (https://doi.org/10.1530/EJE-06-0720)

    • Search Google Scholar
    • Export Citation
  • 47

    Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW & Philips J et al.HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics 2003 40 657663. (https://doi.org/10.1136/jmg.40.9.657)

    • Search Google Scholar
    • Export Citation
  • 48

    Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Toyo K, Robbins CM & Carpten JD et al.Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. New England Journal of Medicine 2003 349 17221729. (https://doi.org/10.1056/NEJMoa031237)

    • Search Google Scholar
    • Export Citation
  • 49

    Erickson LA, Mete O. Immunohistochemistry in diagnostic parathyroid pathology. Endocrine Pathology 2018 29 113129. (https://doi.org/10.1007/s12022-018-9527-6)

    • Search Google Scholar
    • Export Citation
  • 50

    Robertson SP, Twigg SRF, Sutherland-Smith AJ, Biancalana V, Gorlin RJ, Horn D, Kenwrick SJ, Kim CA, Morava E & Newbury-Ecob R et al.Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. Nature Genetics 2003 33 487491. (https://doi.org/10.1038/ng1119)

    • Search Google Scholar
    • Export Citation
  • 51

    Cannaerts E, Shukla A, Hasanhodzic M, Alaerts M, Schepers D, van Laer L, Girisha KM, Hojsak I, Loeys B, Verstraeten A. FLNA mutations in surviving males presenting with connective tissue findings: two new case reports and review of the literature. BMC Medical Genetics 2018 19 140. (https://doi.org/10.1186/s12881-018-0655-0)

    • Search Google Scholar
    • Export Citation
  • 52

    Sickler T, Trarbach EB, Frassetto FP, Dettoni JB, Alves VAF, Fragoso MCBV, Machado MC, Cardoso EF, Bronstein MD, Glezer A. Filamin A and DRD2 expression in corticotrophinomas. Pituitary 2019 22 163169. (https://doi.org/10.1007/s11102-019-00947-x)

    • Search Google Scholar
    • Export Citation
  • 53

    Sun GG, Lu YF, Zhang J, Hu WN. Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion. Tumour Biology 2014 35 38193826. (https://doi.org/10.1007/s13277-013-1504-6)

    • Search Google Scholar
    • Export Citation
  • 54

    Nolte S, Zlobec I, Lugli A, Hohenberger W, Croner R, Merkel S, Hartmann A, Geppert CI, Rau TT. Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients. Journal of Pathology: Clinical Research 2017 3 5870. (https://doi.org/10.1002/cjp2.62)

    • Search Google Scholar
    • Export Citation
  • 55

    Villar Del Moral J, Jiménez-García A, Salvador-Egea P, Martos-Martínez JM, Nuño-Vázquez-Garza JM, Serradilla-Martín M, Gómez-Palacios A, Moreno-Llorente P, Ortega-Serrano J, de La Quintana-Basarrate A. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery 2014 156 11321144. (https://doi.org/10.1016/j.surg.2014.05.014)

    • Search Google Scholar
    • Export Citation
  • 56

    Asare EA, Sturgeon C, Winchester DJ, Liu L, Palis B, Perrier ND, Evans DB, Winchester DP, Wang TS. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the national cancer data base (NCDB) Annals of Surgical Oncology 2015 22 39903995. (https://doi.org/10.1245/s10434-015-4672-3)

    • Search Google Scholar
    • Export Citation
  • 57

    Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, Shen W, Gosnell J, Duh QY, Clark O. Parathyroid carcinoma: a 43-year outcome and survival analysis. Journal of Clinical Endocrinology and Metabolism 2011 96 36793686. (https://doi.org/10.1210/jc.2011-1571)

    • Search Google Scholar
    • Export Citation
  • 58

    Machado NN, Wilhelm SM. Parathyroid cancer: a review. Cancers 2019 11 116. (https://doi.org/10.3390/cancers11111676)

  • 59

    Bollerslev J, Schalin-Jäntti C, Rejnmark L, Siggelkow H, Morreau H, Thakker R, Sitges-Serra A, Cetani F, Marcocci C & Guistina A et al.Unmet therapeutic, educational and scientific needs in parathyroid disorders: consensus statement from the first European Society of Endocrinology Workshop (PARAT). European Journal of Endocrinology 2019 181 119. (https://doi.org/10.1530/EJE-19-0316)

    • Search Google Scholar
    • Export Citation